Shield Therapeutics PLC - Commercial-stage pharmaceutical company focused on iron deficiency product Accrufer - Hires Santosh Shanbhag as chief financial officer, effective next Tuesday. He replaces Hans-Peter Rudolf, who left Shield in October to pursue new opportunities. Shanbhag was previously CFO of Nasdaq-listed Akili Inc, which he "helped transform...from a private to a public entity". Before this, he held various senior finance leadership roles at Vertex Pharmaceuticals Inc, including as Head of International Finance & Accounting.
Chief Executive Officer Greg Madison says: "As we look to build on the impressive growth of Accrufer, I am pleased to have Santosh joining the executive team as a key partner. The breadth of his experience in finance, capital markets, commercial, reimbursement and corporate development from his roles at Akili and Vertex, coupled with his keen operations acumen and strong life sciences background, make him an ideal addition to the executive leadership team at Shield."
Current stock price: 7.12 pence
12-month change: up 15%
By Emma Curzon, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Shield Thera (STX)